Transition has an Alzheimer's drug AZD-103 which is near the beginning of an 18 month phase II trial and is unlikely to generate any catalysts in the near future. The TT-223 diabetes program has been treading water, possibly because the collaboration… More
Another day, another red thumb for a biopharmaceutical! Honestly Transition Therapeutics isn't even close to the worst company I've come across, but its way way way ahead of itself right now. They're trading right now as if their entire pipeline of… More